NewsResearchIs The Worm Turning For CBD? Canopy Growth Says...

Is The Worm Turning For CBD? Canopy Growth Says Toxicity Trial Is A World-First

-

RESEARCH by Canopy Growth subsidiary Spectrum Therapeutics has found CBD increases the lifespan of worms by almost 20%.

Published late November the study examined the long-term effects of cannabidiol (CBD), specifically focusing on toxicity and lifespan effects in Caenorhabditis elegans (C elegans) – a type of threadworm.

Canopy believes it is one of the first long-term toxicity and lifespan research studies examining the effects of chronic exposure to CBD and was commissioned to provide the data required to inform public policy development. 

The C elegans were chosen as up to 80% of their genes are shared with humans, and they have a comparatively short lifespan of less than three weeks. 

The authors say the CBD did not demonstrate any degree of ‘acute or life-long toxicity and demonstrated an extended mean lifespan up to 18% and increased late-stage life activity by up to 206% compared to the untreated controls within the study’.

“Despite widespread use of CBD, no life-long toxicity studies had been conducted to date to determine the impact – or potential impact – of long-term exposure to CBD.

“These results serve as the only CBD life-long exposure data in an in vivo model to date, and the absence of long-term toxicity gives us the evidence we need as an industry to continue researching the potential health benefits for the broader application of CBD,” said Hunter Land, Senior Director of Translational and Discovery Science at Canopy Growth.

The study was conducted in partnership with NemaLife and is published in Cannabis and Cannabinoid Research journal.

This research should prove of interest to those European and UK companies looking for trial data on potential CBD toxicity for their Novel Food applications.

BusinessCann has reported on the ongoing and slated trials which are being undertaken or considered to achieve compliance for CBD brands to remain on sale in the UK market.

After previously regarding CBD as safe, in line with WHO guidelines, the US Food and Drug Administration changed its stance in relation to CBD saying it posed ‘real-risks’ to health.

That was in November, 2019, and in February this year, the UK’s Food Standards Agency (FSA) shifted its position on usage, too. The FSA suggested a cap of 70mg of CBD a day and expressed concerns in relation to its potential harm to the liver.


Peter
Peter McCusker is an experienced news and business editor, who believes it’s time to fully embrace the multiple, proven, medical benefits of the cannabis plant.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest news

Why Can CBD Be A ‘Cure-For-All’ In Europe – But Not The United States?

By Liebe Griebenauw and Peter McCusker FOUR firms have been sanctioned in the latest crackdown by the United States Food...

Markets: PepsiCo Launches German Hemp Drink, Curaleaf’s $130m Backer, Organigram, Canopy Growth, Fyllo et al…

FOLLOWING its recent purchase of UK cannabis firm EMMAC Life Sciences, Curaleaf has now secured an additional $130m from...

Euro Cannabis Leader Alfredo Pascual To Join UK Investor With £12m-Plus To Deploy

UK investment fund Fast Forward Innovations has added Alfredo Pascual - one of Europe’s leading cannabis industry figures -...

Love Hemp Raises £5m With A London Stock Exchange Flotation In Sight

FAST-GROWING UK CBD business Love Hemp has unveiled plans to list on the London Stock Exchange backed by an...

CBD Marketplace Mellow Expanding Rapidly With New B2B and B2C Offerings

THE marketplace entrepreneurs behind the mellow platform are diversifying with the launch of a new e-commerce service for partner...

Dutch/Canadian Duopoly In European Medicinal Cannabis Market In Retreat

THE European medicinal cannabis supply stranglehold once enjoyed by Canada and the Netherlands is being disrupted, concludes Prohibition Partners...

Must read

Why Can CBD Be A ‘Cure-For-All’ In Europe – But Not The United States?

By Liebe Griebenauw and Peter McCusker FOUR firms have been...

Euro Cannabis Leader Alfredo Pascual To Join UK Investor With £12m-Plus To Deploy

UK investment fund Fast Forward Innovations has added Alfredo...

You might also likeRELATED
Recommended to you